Close Menu

NEW YORK – Bruker reported after the close of the market Wednesday that its first quarter revenues fell 8 percent year over year.

For the three months ended March 31, the firm said total revenues fell to $424.0 million from $461.4 million in the first quarter of 2019, below analysts' consensus estimate of $444.4 million.

Bruker's organic revenue was down 8 percent year over year, with growth from acquisitions of 1 percent countering a 1 percent negative effect from changes in foreign currency rates.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.

Sep
09
Sponsored by
10x Genomics

Recent advances in spatially resolved transcriptomics have greatly expanded the knowledge of complex multicellular biological systems.